What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Enzyme
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Renin–angiotensin system, Angiotensin II and Receptor.
His Internal medicine study which covers Cardiology that intersects with Transplantation.
His research investigates the link between Endocrinology and topics such as Endothelin 1 that cross with problems in Endothelin receptor and Preeclampsia.
His work deals with themes such as Aldosterone, Angiotensin-converting enzyme, ACE inhibitor, Circulatory system and Pharmacology, which intersect with Renin–angiotensin system.
His work in Angiotensin II receptor type 1 and Angiotensin receptor is related to Angiotensin II.
His biological study spans a wide range of topics, including Signal transduction, Cell biology and In vivo.
His most cited work include:
- Angiotensin-Converting Enzyme in the Human Heart: Effect of the Deletion/Insertion Polymorphism (694 citations)
- Effects of Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women (335 citations)
- Hypertension Renin–Angiotensin–Aldosterone System Alterations (291 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Endocrinology, Renin–angiotensin system, Angiotensin II and Receptor.
His Internal medicine study frequently draws connections to other fields, such as Cardiology.
His Angiotensin II receptor type 1, Kidney, Aldosterone, Angiotensin-converting enzyme and Angiotensin receptor investigations are all subjects of Endocrinology research.
The Renin–angiotensin system study combines topics in areas such as Vasoconstriction, Blockade and Pharmacology.
His Angiotensin II study incorporates themes from Irbesartan, Endothelium and Receptor antagonist.
The concepts of his Receptor study are interwoven with issues in Diabetes mellitus, Vascular smooth muscle, Intracellular and In vivo.
He most often published in these fields:
- Internal medicine (76.20%)
- Endocrinology (65.44%)
- Renin–angiotensin system (50.71%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (76.20%)
- Endocrinology (65.44%)
- Renin–angiotensin system (50.71%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Endocrinology, Renin–angiotensin system, Pharmacology and Preeclampsia.
A.H. Jan Danser has researched Internal medicine in several fields, including Diabetes mellitus, Downregulation and upregulation and Cardiology.
Endocrinology is closely attributed to Sildenafil in his work.
His Renin–angiotensin system research incorporates elements of Receptor, Angiotensin II, Aldosterone and Reabsorption.
His Pharmacology study combines topics from a wide range of disciplines, such as Coronary arteries, Sitaxentan, Phosphodiesterase and Small interfering RNA.
His Preeclampsia research includes themes of Vascular endothelial growth factor A, Vascular endothelial growth factor, Fetus and Nephropathy.
Between 2018 and 2021, his most popular works were:
- Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. (281 citations)
- Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. (101 citations)
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial (67 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Enzyme
Pharmacology, Renin–angiotensin system, Internal medicine, Receptor and Angiotensin II are his primary areas of study.
His Renin–angiotensin system study combines topics in areas such as Acute kidney injury, RNAi Therapeutics, Small interfering RNA and Heart disease.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology and Cardiology.
His research integrates issues of Ex vivo, Perfusion and Vinpocetine in his study of Endocrinology.
His study in the field of Sumatriptan also crosses realms of Lasmiditan.
His Angiotensin II research includes elements of Blockade, Combination therapy, Homeostasis and Genetic enhancement.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
